RESEARCH ACTIVITIES DURING #Covid19

12/3/20  SUMMARY BY: DR DAVID LYNNESS  ESICM EDITORIAL AND PUBLISHING COMMITTEE

LOCAL INITIATIVES
LOTS OF LOCAL INITIATIVES ONGOING - CHECK YOUR LOCAL TRUST OR HOSPITAL.

OBSERVATIONAL 'STUDY' - BY ISARIC
ISARIC IS A NON-COMMERICAL AND A NETWORK OF NETWORKS
CONSISTS OF A CRF (CASE REPORT FORM)
CLINICIANS CAN UPLOAD AND SAVE LOCALLY OR UPLOAD TO CLOUD SERVER

CLINICAL CHARACTERISATION PROTOCOL - BY ISARIC
GLOBAL INITIATIVE
TIERED APPROACH TO SAMPLING (LABS)
COLLECT AND STORE THESE SAMPLES THEN SHIP TO LAB-HUBS
DATA IS ANALYSED AND SHARED
LED BY DR. KENNETH BAILIE

GLOBAL INTERNATIONAL TRIAL OF REMAP-CAP
A RANDOMISED, EMBEDDED, MULTI-FACTORIAL, ADAPTIVE PLATFORM TRIAL FOR COMMUNITY-ACQUIRED PNEUMONIA [REMAP-CAP]
PROVIDES A GLOBAL RESEARCH PLATFORM THAT IS ABLE TO ADAPT TO EFFICIENTLY EVALUATE MULTIPLE TREATMENT OPTIONS FOR PATIENTS WHO ARE CRITICALLY ILL DUE TO A GLOBAL RESPIRATORY PANDEMIC.
INTERNATIONAL COLLABORATION
ADAPTIVE RESEARCH TRIAL - HELPS TO EVALUATE EMERGING TREATMENT OPTIONS QUICKER
TRIAL CAN BE MODIFIED FOR EFFICIENCY
PROTOCOLS HAVE BEEN APPROVED BY THE INSTITUTIONAL REVIEW BOARDS IN MANY COUNTRIES
COVID-19 IS INCLUDED AND THE CASE REPORT FORMS ARE READY
TRAINING AND STANDARD OPERATING PROCEDURES ARE PREPARED
ORIGINALLY SET UP 6 YEARS AGO SPECIFICALLY FOR RESEARCH DURING A PANDEMIC

“SPECIAL PANDEMIC STUDY” STATUS WITH 'WHO'
AND IS ENDORSED AND FUNDED BY EUROPEAN COMMITTEE

SPECIFIC TO COVID-19
DOMAIN 1: LOPINAVIR/ritaNAvIR VS NIL
DOMAIN 2: INTERFeRON VS ANaKINRA VS NIL

THE ELIGIBLE PATIENTS RECEIVE PHARMACOTHERAPY FROM EACH DOMAIN
THERE WILL ALSO BE ALL COMBINATIONS OF DOMAIN 1 AND 2 INTERVENTIONS
POTENTIALLY MORE DRUG ADDITIONS TO COME (PENDING)

THESE ARE NOT CLINICAL GUIDELINES. GENERAL EDUCATIONAL INFORMATION ONLY.

SEE ALSO:
WWW.WHO.INT
WWW.GLOPID-R.ORG
WWW.ISARIC.TGHN.ORG
WWW.ECDC.EUROPA.EU